Home › NDC Lookup › J-codes › J9039
J9039

J9039 – Injection, blinatumomab, 1 microgram · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 2 NDCs crosswalked per 1 MCG $172.900/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J9039 summary

J9039 is a HCPCS Level II J-code used to bill blinatumomab, 1 microgram, billed per 1 MCG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J9039: Blincyto

Code J9039 Billing unit 1 MCG Payment limit $172.900/unit NDC-Crosswalk 2 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9039
DescriptorInjection, blinatumomab, 1 microgram
Billing unit1 MCG
Payment limit / unit$172.900
Est. ASP / unit$163.113 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$172.900
Est. ASP / unit
$163.113 est.
Est. after 2% sequester
$169.442
HCPCS dosage
1 MCG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, blinatumomab, 1 microgram
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2016-01-01
Date added2016-01-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9039 = 1 mcg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9039 WITH EST. MEDICARE PAY

2 NDCs map to J9039. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($172.900/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
55513-0160-01 BLINCYTO blinatumomab KIT Amgen, 1 KIT in 1 PACKAGE (55513-160-01) * 3.08... — 35 $6,051.50 — ● Active CMS + PDAC
55513-0150-01 BLINCYTO (INNER VIAL NDC,PF) 35 MCG Unknown — — 35 $6,051.50 — — PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$28.12M
Claims
933
Beneficiaries
183
Spend / beneficiary
$153,672.34
Spend / claim
$30,141.52
Trend by period
Where J9039 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #106 of 824
#101 ARANESP(J0881) J0881 $31.07M #102 VEGZELMA Q5129 $30.16M #103 FLUZONE HIGH-DOSE * 90662 $29.64M #104 DATROWAY J9011 $29.34M #105 ALTUVIIIO J7214 $29.24M #106 BLINCYTO J9039 $28.12M #107 SKYRIZI J2327 $27.14M #108 AVASTIN J9035 $27.11M #109 RYTELO J0870 $26.72M #110 INJECTAFER J1439 $25.65M #111 JEVTANA J9043 $25.22M
Total claims — #380 of 824
#375 TEPEZZA J3241 985 #376 POTELIGEO J9204 976 #377 LANREOTIDE ACETATE(J... J1932 970 #378 APRETUDE J0739 959 #379 OASIS ULTRA Q4124 939 #380 BLINCYTO J9039 933 #381 MANNITOL(J2151) J2151 925 #382 BEOVU J0179 920 #383 CABENUVA J0741 920 #384 ORPHENADRINE CITRATE J2360 916 #385 PEMRYDI RTU J9324 903

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $28.12M 183 933 $153,672.34 $30,141.52
2025 (Q1-Q4) $101.13M 397 3,602 $254,733.65 $28,075.86
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$33.28M
Medicare paid
$26.5M
Submitted services
232,510
Denial rate
9.3%
Allowed / service
$157.89
Submitted charges
$104.32M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

📊 What bills under J9039

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
blinatumomab 1
NDC products by labeler
Amgen, Inc 1

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9039 billing FAQ

What is HCPCS code J9039?
J9039 is a HCPCS Level II J-code used to bill Injection, blinatumomab, 1 microgram under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9039?
One unit of J9039 represents 1 MCG. Report the number of units equal to the dose administered divided by 1 MCG.
How many units of J9039 should I bill?
Divide the dose administered by the code's unit size (1 MCG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9039?
The Medicare Part B payment limit is $172.900 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $169.442 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9039?
2 NDCs currently map to J9039 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9039 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.